Please login to the form below

Not currently logged in
Email:
Password:

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

 Celgene HQ

The global multiple myeloma treatment market value will expand from $7.3bn in 2014 to $8.9bn by 2021.

This is according to new research business intelligence provider GBI Research, which says that this represents a moderate Compound Annual Growth Rate (CAGR) of 4.6%.

The company's latest report states that this increase, which will occur across the eight major markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada, and will be driven primarily by rising multiple myeloma prevalence as a result of an aging population.

Additionally, approvals during the forecast period for drugs that will supplement the current market leader - Celgene's $4.9bn a year Revlimid (lenalidomide) - and offer improved therapeutic options, mainly in the relapsed/refractory setting, will also boost the market.

Promising examples include Takeda's oral drug ixazomib, which is currently acing late-stage trials, and Array Biopharma's filanesib, as well as BMS/AbbVie's candidate elotuzumab and Janssen's daratumumab.

Yasser Mushtaq, senior analyst for GBI Research, says: “Although multiple myeloma remains incurable, greater understanding of its underlying cellular and molecular biology has driven novel therapy development, with clinical outcomes improving significantly as a result.

“While some late-stage pipeline drugs will have a low impact, others have demonstrated promising clinical results in specific patient populations, including elotuzumab and daratumumab. These products are therefore likely to provide physicians with increased choice and complexity in multiple myeloma treatment over the forecast period.”

However, the analyst adds that various market barriers, such as a limited target patient population, will restrict any further growth in the multiple myeloma therapeutics arena by 2021.

Mushtaq explains: “Multiple myeloma's rarity and designation as an orphan disease limits the available treatment population, in turn hindering the potential revenues that can be generated from this indication. This, combined with high drug development costs, can deter manufacturers from investing in this area.

“On the other hand, incentives for orphan disease drug development, along with the ability to reposition drugs from one indication to another, could help to counter these challenges and drive further research into multiple myeloma treatment,” the analyst concludes.

Article by
Ben Adams

21st August 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Digital
Tools for the digital world
The next step for the pharma industry...
How Can We Make Payer Communications Really Sing?
With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...

Infographics